Overdose Unknown: How Anebulo Pharmaceuticals Is Working to Solve a Growing Marijuana Overdose Problem
Photo by Elsa Olofsson on
The Unintended Consequences of Ever-Increasing Marijuana Potency
Photo by Tim Foster on Unsplash
CBD-Focused Anebulo Pharma Posts Q4 & Full Year 2021 Earnings, Launching Phase 2 Cannabis Overdose Clinical Trials
Cannabinoid-focused biotech company Anebulo Pharmaceuticals, Inc. (NASDAQ: ANEB) announced its financial results Wednesday for the three and 12 months ended June 30.
Anebulo Pharmaceuticals Q4 EPS $(1.59)
Anebulo Pharmaceuticals (NASDAQ:ANEB) reported quarterly losses of $(1.59) per share.
Cannabis Edibles are Leading to More Negative Outcomes in Cannabis Users
Photo by camilo jimenez on Unsplash
CB1 Antagonists as a Solution to the Complicated Problems of Cannabis Over-intoxication
The legalization of recreational cannabis in a number of states is associated with the increasing problem of acute cannabis intoxication (ACI).
Anebulo is Developing an Antidote to Cannabis Intoxication
The company Anebulo Pharmaceuticals (NASDAQ: ANEB) is investing in an antidote for cannabis intoxication. The social and medical issues associated with acute cannabis intoxication (ACI) are often underestimated, because of the perceived lack of risk of cannabis overdose.
Cannabis Legalization is Driving an Increase in Related ER Visits
The legalization of both medical use and recreational use of cannabis in the United States has lead to an increase in both availability and potency.